IQVIA HOLDINGS INC.
IQVAPI behind this page
IQV Q2 2025 request
Playground key active
/api/financials?ticker=IQV&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 4,017 | 3,814 | +5.3% |
Show Business Segments breakouts |
|||
| Contract Sales & Medical Solutions | 188 | 172 | +9.3% |
| Contract Sales & Medical Solutions · Americas | 68 | 66 | +3.0% |
| Contract Sales & Medical Solutions · Asia Pacific | 60 | 54 | +11.1% |
| Contract Sales & Medical Solutions · EMEA | 60 | 52 | +15.4% |
| Contract Sales & Medical Solutions · Operating Segments | 188 | 172 | +9.3% |
| Research & Development Solutions | 2,201 | 2,147 | +2.5% |
| Research & Development Solutions · Americas | 1,037 | 1,014 | +2.3% |
| Research & Development Solutions · Asia Pacific | 629 | 576 | +9.2% |
| Research & Development Solutions · EMEA | 535 | 557 | -3.9% |
| Research & Development Solutions · Operating Segments | 2,201 | 2,147 | +2.5% |
| Technology & Analytics Solutions | 1,628 | 1,495 | +8.9% |
| Technology & Analytics Solutions · Americas | 830 | 783 | +6.0% |
| Technology & Analytics Solutions · Asia Pacific | 152 | 143 | +6.3% |
| Technology & Analytics Solutions · EMEA | 646 | 569 | +13.5% |
| Technology & Analytics Solutions · Operating Segments | 1,628 | 1,495 | +8.9% |
Show Geography breakouts |
|||
| Americas | 1,935 | 1,863 | +3.9% |
| Asia Pacific | 841 | 773 | +8.8% |
| EMEA | 1,241 | 1,178 | +5.3% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax | 3 | 15 | -80.0% |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Forward · Sales | 2 | — | — |
| Interest Rate Swap · Interest Expense | 1 | 15 | -93.3% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Tax | -1 | -4 | +75.0% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax | -2 | -11 | +81.8% |
| Cost Of Goods And Service Excluding Depreciation Depletion And Amortization | 2,694 | 2,488 | +8.3% |
Show Business Segments breakouts |
|||
| Contract Sales & Medical Solutions · Operating Segments | 162 | 148 | +9.5% |
| Research & Development Solutions · Operating Segments | 1,523 | 1,431 | +6.4% |
| Technology & Analytics Solutions · Operating Segments | 1,009 | 909 | +11.0% |
| Selling, General & Administrative | 509 | 509 | 0.0% |
Show Business Segments breakouts |
|||
| Contract Sales & Medical Solutions · Operating Segments | 14 | 15 | -6.7% |
| Research & Development Solutions · Operating Segments | 227 | 223 | +1.8% |
| Technology & Analytics Solutions · Operating Segments | 230 | 225 | +2.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 471 | 463 | +1.7% |
| Depreciation & Amortization | 276 | 269 | +2.6% |
| Restructuring Charges | 32 | 28 | +14.3% |
| Operating Income | 506 | 520 | -2.7% |
| Interest Income | -10 | -12 | +16.7% |
| Interest Expense | 182 | 163 | +11.7% |
| Other Non-Operating Income (Expense) | 11 | -67 | +116.4% |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | 323 | 436 | -25.9% |
| Income Tax Expense (Benefit) | 56 | 75 | -25.3% |
| Income Loss From Continuing Operations After Income Taxes And Before Equity In Earnings Of Unconsolidated Affiliates | 267 | 361 | -26.0% |
| Income Loss From Equity Method Investments | -1 | 2 | -150.0% |
| Net Income | 266 | 363 | -26.7% |
Show Equity Components breakouts |
|||
| Retained Earnings | 266 | 363 | -26.7% |
| EPS (Basic) | 1.55 | 1.99 | -22.1% |
| EPS (Diluted) | 1.54 | 1.97 | -21.8% |
| Wtd Avg Shares (Basic) | 171.8 | 182.2 | -5.7% |
| Wtd Avg Shares (Diluted) | 173.2 | 184.3 | -6.0% |
| Gross Profit (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Contract Sales & Medical Solutions · Operating Segments | 12 | 9 | +33.3% |
| Research & Development Solutions · Operating Segments | 451 | 493 | -8.5% |
| Technology & Analytics Solutions · Operating Segments | 389 | 361 | +7.8% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -38 | -46 | +17.4% |
| Operating Segments | 852 | 863 | -1.3% |
| Net Income | 266 | 363 | -26.7% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | -4 | 15 | -126.7% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -4 | 15 | -126.7% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,039 | 1,545 | +32.0% |
| Trade Accounts Receivable And Unbilled Services Net | 3,344 | 3,255 | +2.7% |
| Prepaid Expense Current | 200 | 191 | +4.7% |
| Income Taxes Receivable | 62 | 41 | +51.2% |
| Marketable Securities (Current) | 149 | 133 | +12.0% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level1 · Fair Value Measurements Recurring | 182 | 156 | +16.7% |
Show Fair Value By Measurement Frequency breakouts |
|||
| Fair Value Measurements Recurring | 182 | 156 | +16.7% |
| Other Assets Current And Receivables | 551 | 457 | +20.6% |
| Total Current Assets | 6,345 | 5,622 | +12.9% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 536 | 503 | +6.6% |
| Operating Lease Right-of-Use Assets | 280 | 265 | +5.7% |
| Goodwill | 15,611 | 14,477 | +7.8% |
Show Business Segments breakouts |
|||
| Contract Sales & Medical Solutions | 149 | 146 | +2.1% |
| Research & Development Solutions | 2,716 | 2,431 | +11.7% |
| Technology & Analytics Solutions | 12,746 | 11,900 | +7.1% |
Show Business Acquisition breakouts |
|||
| Series Of Individually Immaterial Business Acquisitions | 236 | 147 | +60.5% |
| Deferred Tax Assets | 345 | 158 | +118.4% |
| Deposits And Other Assets Noncurrent | 513 | 478 | +7.3% |
| Total Assets | 28,632 | 26,398 | +8.5% |
| Other Assets | |||
| Long Term Investments Excluding Equity Method Investments | 134 | 106 | +26.4% |
| Equity Method Investments | 272 | 181 | +50.3% |
| Intangible Assets Net Excluding Goodwill | 4,596 | 4,608 | -0.3% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level3 · Fair Value Measurements Nonrecurring | 4,596 | 4,608 | -0.3% |
| Current Liabilities | |||
| Accounts Payable And Other Accrued Liabilities Current | 3,399 | 3,313 | +2.6% |
| Deferred Revenue (Current) | 2,123 | 1,811 | +17.2% |
| Accrued Income Taxes Current | 124 | 185 | -33.0% |
| Current Portion of Long-Term Debt | 1,313 | 1,167 | +12.5% |
| Other Liabilities Current | 613 | 144 | +325.7% |
| Total Current Liabilities | 7,572 | 6,620 | +14.4% |
| Non-Current Liabilities | |||
| Long-Term Debt | 14,177 | 12,091 | +17.3% |
| Deferred Tax Liabilities | 216 | 149 | +45.0% |
| Operating Lease Liabilities | 210 | 192 | +9.4% |
| Other Non-Current Liabilities | 671 | 632 | +6.2% |
| Total Liabilities | 22,846 | 19,684 | +16.1% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Net Investment Hedging · Designated As Hedging Instrument | 2,665 | 2,688 | -0.9% |
| Stockholders' Equity | |||
| Common Stocks Including Additional Paid In Capital | 11,225 | 11,061 | +1.5% |
| Retained Earnings | 6,580 | 5,343 | +23.2% |
| Treasury Stock Common Value | -11,145 | -8,741 | -27.5% |
| Accumulated Other Comprehensive Income | -882 | -949 | +7.1% |
| Total Stockholders' Equity | 5,778 | 6,714 | -13.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 11 | 3 | +266.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -34 | 4 | -950.0% |
| Accumulated Other Comprehensive Income | -882 | -949 | +7.1% |
| Accumulated Translation Adjustment | -1,050 | -1,030 | -1.9% |
| Minority Interest | 8 | — | — |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 5,786 | 6,714 | -13.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -882 | -949 | +7.1% |
| Additional Paid In Capital | 11,222 | 11,058 | +1.5% |
| Common Stock | 3 | 3 | 0.0% |
| Noncontrolling Interest | 8 | — | — |
| Retained Earnings | 6,580 | 5,343 | +23.2% |
| Treasury Stock Common | -11,145 | -8,741 | -27.5% |
| Total Liabilities & Equity | 28,632 | 26,398 | +8.5% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Amortization Of Financing Costs And Discounts | 11 | 11 | 0.0% |
| Stock-Based Compensation | 132 | 104 | +26.9% |
| Income Loss From Equity Method Investments Net Of Dividends Or Distributions | 14 | 1 | +1300.0% |
| Gain Loss On Sale Of Investments | -16 | -12 | -33.3% |
| Deferred Income Taxes | -86 | -80 | -7.5% |
| Increase Decrease In Accounts Receivable Unbilled Services And Unearned Income | 269 | 187 | +43.9% |
| Increase Decrease In Other Operating Capital Net | -369 | -285 | -29.5% |
| Net Cash from Operations | 1,011 | 1,110 | -8.9% |
| Change in Deferred Revenue | 344 | 12 | +2766.7% |
| Investing Activities | |||
| Payments To Acquire Productive Assets | -293 | -288 | -1.7% |
| Payments To Acquire Businesses Net Of Cash Acquired | -315 | -221 | -42.5% |
| Payments For Proceeds From Investments | 2 | — | — |
| Payments To Acquire Equity Method Investments And Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital | -27 | -49 | +44.9% |
| Payments For Proceeds From Investments Excluding Marketable Securities | -19 | -2 | -850.0% |
| Other Investing Activities | 1 | — | — |
| Net Cash from Investing | -651 | -535 | -21.7% |
| Financing Activities | |||
| Proceeds From Issuance Of Debt | 3,985 | — | — |
| Debt Issuance Costs | -35 | — | — |
| Repayments Of Debt And Capital Lease Obligations | -2,140 | -86 | -2388.4% |
| Proceeds From Lines Of Credit | 875 | 375 | +133.3% |
| Repayments Of Lines Of Credit | -1,700 | -585 | -190.6% |
| Payments For Stock Options Exercised | -35 | -60 | +41.7% |
| Share Repurchases | -1,032 | — | — |
| Payment For Contingent Consideration Liability Financing Activities | -20 | -10 | -100.0% |
| Proceeds From Payments For Other Financing Activities | -11 | — | — |
| Net Cash from Financing | -113 | -366 | +69.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 90 | -40 | +325.0% |
| Net Change in Cash | 337 | 169 | +99.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,039 | 1,545 | +32.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.